<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245970</url>
  </required_header>
  <id_info>
    <org_study_id>4222</org_study_id>
    <nct_id>NCT03245970</nct_id>
  </id_info>
  <brief_title>Impedance Cardiography to Decrease the Risk of Preeclampsia</brief_title>
  <official_title>Use of Impedance Cardiography to Decrease the Risk of Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the use of impedance cardiography can identify appropriate medications for&#xD;
      use in treating chronic hypertensive patients to decrease the risk of preeclampsia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Impedance cardiography helps determine whether vasoconstriction or an elevated cardiac output&#xD;
      is occurring. The test is easy to perform and non invasive. The treatment for an elevated&#xD;
      cardiac output in pregnancy is a beta-blocker while a vasodilator is used for&#xD;
      vasoconstriction. If a beta-blocker is given to someone that vasoconstricted, this might make&#xD;
      the cardiovascular parameters worse, leading to no improvement in future pregnancy issues.&#xD;
      Likewise, if a vasoconstricting drug is given to someone with an elevated cardiac output, it&#xD;
      could potentially make the cardiovascular parameters worse.&#xD;
&#xD;
      All centers in the United States that choose to prescribe an antihypertensive medication for&#xD;
      use in pregnancy do so by trial and error, whereas impedance cardiography can help the&#xD;
      clinician choose the best medication from the start. Many pregnant patient patients have&#xD;
      chronic hypertension and this population is at increased risk for superimposed preeclampsia&#xD;
      and other pregnancy complications. The current recommendation for pregnancy is to NOT treat&#xD;
      mild hypertension because studies have not shown any benefit. These studies, have also not&#xD;
      shown any harm. Prior studies that have shown no benefit to treatment of mild hypertension in&#xD;
      pregnancy may be hampered by choosing the wrong antihypertensive medication, thereby not&#xD;
      improving the rate of superimposed preeclampsia and other pregnancy related complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator retired. Other investigators did not want to continue study.&#xD;
  </why_stopped>
  <start_date type="Actual">April 24, 2017</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization to treatment or non treatment group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of preeclampsia in chronically hypertensive pregnant women</measure>
    <time_frame>2 years</time_frame>
    <description>Rates of preeclampsia in chronically hypertensive pregnant women</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Hypertension Complicating Pregnancy (Diagnosis)</condition>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.&#xD;
Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Labetalol Hydrocholoride 200 mg orally every 12 hours</intervention_name>
    <description>Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Trandate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine 60 mg orally daily</intervention_name>
    <description>Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Procardia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol 25 mg daily</intervention_name>
    <description>Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Tenormin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Pregnant patients 18-51 years old Less than 20 weeks gestation with mild chronic&#xD;
        hypertension - Not on antihypertensive medications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with an allergy to antihypertensive medication or contraindication for their usage&#xD;
        such as certain cardiac or neurologic disorder during pregnancy Patients who have a blood&#xD;
        pressure 140/90 or greater -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Fortner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIgh Risk Obstetrical Consultants</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 8, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Labetalol</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

